Valuation: Shanghai Rightongene Biotechnology Co., Ltd.

Market Cap 1.12B 168M 150M 138M 125M 238M 15.77B 244M 1.65B 659M 8.44B 631M 618M 26.59B P/E 2024
-65.9x
P/E 2025 -29x
Enterprise Value 901M 135M 120M 111M 101M 191M 12.65B 195M 1.33B 528M 6.77B 506M 496M 21.32B EV / Sales 2024
3.33x
EV / Sales 2025 6.95x
Free-Float
62.91%
Yield 2024 *
-
Yield 2025 0.65%
10-29 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2026 CI
08-27 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 CI
04-27 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
02-27 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
16/10/25 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
08/09/25 Shanghai Rightongene Biotechnology's boards elects chairman RE
28/08/25 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
24/04/25 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
27/02/25 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
25/02/25 Shanghai Rightongene Biotechnology Receives 1.8 Million Yuan in Government Subsidies MT
20/02/25 Tranche Update on Shanghai Rightongene Biotechnology Co., Ltd.'s Equity Buyback Plan announced on February 29, 2024. CI
18/02/25 Shanghai Rightongene Biotechnology Co., Ltd.'s Equity Buyback announced on February 29, 2024, has closed with 669,621 shares, representing 1.2% for CNY 17.02 million. CI
03/01/25 Tranche Update on Shanghai Rightongene Biotechnology Co., Ltd.'s Equity Buyback Plan announced on February 29, 2024. CI
1 day-2.96%
1 week+0.89%
Current month+0.89%
1 month-19.37%
3 months-12.25%
6 months-32.73%
Current year-22.77%
1 week 19.58
Extreme 19.58
21.41
1 month 19.58
Extreme 19.58
25.17
Current year 17.81
Extreme 17.81
33.27
1 year 17.81
Extreme 17.81
33.27
3 years 12.38
Extreme 12.38
43.05
5 years 12.38
Extreme 12.38
86.39
10 years 12.38
Extreme 12.38
133.67
Manager TitleAgeSince
Chief Executive Officer 69 22/07/2024
Director of Finance/CFO 34 27/01/2025
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 53 24/08/2023
Chairman 69 22/07/2024
Director/Board Member 41 13/05/2019
Change 5-day change 1-year change 3-year change Capi.($)
-2.96%+0.89%-29.14%-47.47% 173M
+0.62%+0.41%-12.14%+18.24% 190B
+1.49%+4.05%+11.50%+47.40% 125B
+0.56%+6.69%-7.80%+20.86% 124B
-1.65%+1.98%-38.87%+8.64% 99.31B
+3.84%+2.75%-4.81%+76.37% 63.65B
+2.03%+8.85%+19.01%-6.92% 57.71B
+4.07%+4.61%-0.98%+67.79% 53.26B
+3.53%-11.54%-8.86%+50.02% 47.03B
-0.13%+1.32%+2.89%-7.69% 36.15B
Average +1.12%+4.59%-6.92%+22.72% 79.64B
Weighted average by Cap. +1.17%+5.55%-6.63%+28.84%

Financials

2024 2025
Net sales 242M 36.3M 32.4M 29.81M 27.06M 51.28M 3.4B 52.55M 357M 142M 1.82B 136M 133M 5.74B 177M 26.56M 23.7M 21.81M 19.8M 37.52M 2.49B 38.45M 261M 104M 1.33B 99.67M 97.54M 4.2B
Net income -15.76M -2.36M -2.11M -1.94M -1.76M -3.34M -221M -3.42M -23.2M -9.25M -119M -8.86M -8.67M -373M -50.38M -7.55M -6.74M -6.2M -5.63M -10.66M -707M -10.93M -74.15M -29.56M -379M -28.33M -27.72M -1.19B
Net Debt -210M -31.5M -28.12M -25.88M -23.49M -44.51M -2.95B -45.61M -310M -123M -1.58B -118M -116M -4.98B -222M -33.33M -29.75M -27.37M -24.84M -47.08M -3.12B -48.25M -327M -131M -1.67B -125M -122M -5.27B
Projected Income Statement - Annual - Shanghai Rightongene Biotechnology Co., Ltd.
Logo Shanghai Rightongene Biotechnology Co., Ltd.
Shanghai Rightongene Biotechnology Co Ltd is a China-based company mainly engaged in the research and development, production, sales, scientific research, and testing services of in vitro diagnostic products. The Company mainly provides self-branded molecular diagnostic reagents, scientific research services, testing services, and molecular testing equipment. The Company's main products are molecular diagnostic kits for leukemia, lymphoma, solid tumors, and infectious disease related genes. The Company's main services include providing third-party medical testing services for various medical institutions, pharmaceutical companies, individual patients, and others, as well as providing genetic testing research services for research hospitals, pharmaceutical companies, scientific research institutions, third-party testing institutions and other enterprises and institutions.
Employees
327
Date Price Change Volume
09/11/26 CN¥20.35 -2.96% 1,003,882
06/11/26 CN¥20.97 -1.18% 952,231
05/11/26 CN¥21.22 +3.31% 948,273
04/11/26 CN¥20.54 +1.38% 1,159,222
03/11/26 CN¥20.26 -2.22% 987,529

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Shanghai Rightongene Biotechnology Co., Ltd.
  1. Stock Market
  2. Stocks
  3. 688217 Stock